- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05065021
Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor
Re-VOLVE: A Phase II Clinical Trial in Women With Ovarian Cancer Progressing Post-PARP Inhibitor With Treatment Adapted to Real-time Assessment of Evolving Genomic Resistance
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Participants who join the study will first have samples of their blood and tumor tissue collected for biomarker testing. The testing will involve a method called "sequencing". This test will look for changes in the genes of your tumor. The results of the testing will be what is called the participant's molecular profile.
All participants will first receive bevacizumab and niraparib for 3 cycles. A cycle will be 21-days in length.
Once the participant's molecular profile has been determined, the study doctor will discuss the results with the participants and they may be referred to a genetic counsellor.
Participants will then be assigned to a study cohort (group) and receive a combination of the study drugs based on the results of their genetic testing:
- Cohort A: Participants who do not have the required gene changes will be assigned to receive niraparib, bevacizumab, and dostarlimab
- Cohort B: Participants who have certain gene changes will receive paclitaxel, bevacizumab, and dostarlimab.
- Cohort C: If the participant and the study doctor think that the participant is benefitting from the combination of bevacizumab and niraparib, or the molecular profile shows that bevacizumab and niraparib is the most suitable, the participant may continue to receive this drug combination.
Participants will receive the study drug combination until disease worsening or they meet the criteria for discontinuation.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Stephanie Lheureux, M.D.
- Phone Number: 416-946-2818
- Email: stephanie.lheureux@uhn.ca
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2M9
- Recruiting
- Princess Margaret Cancer Centre
-
Contact:
- Stephanie Lheureux, M.D.
- Phone Number: 416-946-2818
- Email: stephanie.lheureux@uhn.ca
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
- Histologically confirmed ovarian, fallopian tube or primary peritoneal cancer, high grade serous or high grade endometrioid histology subtype.
- Patients must have relapsed disease, either platinum-sensitive, resistant or refractory, with no limit to number of lines of prior systemic therapy.
- Radiographically documented disease progression within 28 days of registration.
- Patient must have measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
- Progression on any prior Poly (ADP-ribose) polymerase (PARP) inhibitor therapy, with no limit to number of prior lines of PARP inhibitors.
- Patients must have adequate bone marrow, renal and hepatic function within 7 days of registration
- Left ventricular ejection fraction (LVEF) > 50% by echocardiograms or multigated acquisition (MUGA) scan within 28 days of registration.
- Patients are willing to undergo tumor biopsy pre-treatment (tissue at the time of progression on PARP inhibitor therapy).
- Availability of archival tissue (prior to PARP inhibitor therapy) for analysis.
- Women of child-bearing potential must agree to use a highly effective contraceptive method for study-required period. A negative high sensitive urine or serum pregnancy test within 3 days prior to the initiation of therapy will be required for women of childbearing potential.
- Patient must agree to not donate blood during the study or for 90 days after the last dose of study treatment.
- Patient must agree to not breastfeed during the study or for 30 days after the last dose of study treatment.
Exclusion Criteria:
- Treatment with an investigational (other than PARP inhibitor) drug within 30 days and treatment with PARP inhibitor within 14 days prior to the first dose of study medication.
- Major surgery within 4 weeks of registration or ongoing clinically significant post-surgical complications.
- Patients with current or are at high-risk of developing fistula, or any other gastrointestinal disorders likely to interfere with absorption of the study medication.
- Patients with current or history of bowel obstruction within the last 3 months.
- Untreated unstable brain or leptomeningeal metastases.
- Greater than +1 proteinuria on two consecutive dipsticks within 14 days of registration.
- Unresolved toxicity of > grade 1 from previous anti-cancer therapy (including radiotherapy).
.History of poorly controlled hypertension or resting blood pressure >140/90 mmHg in the presence or absence of a stable regimen of anti-hypertensive therapy within 7 days of registration.
- Mean QTc >470 msec in screening electrocardiograms within 7 days of registration or history of familial long QT syndrome.
- Any evidence of severe or uncontrolled diseases such as but not limited to unstable or uncompensated respiratory, cardiac, hepatic, renal disease or psychiatric illness/social situations that would limit compliance with study requirements.
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to bevacizumab, paclitaxel, dostarlimab, or niraparib.
- Patients who have received prior weekly paclitaxel in the recurrent ovarian cancer setting.
- Patients who have received prior PD-1 inhibitor for ovarian cancer.
- Active autoimmune disease that has required systemic treatment in the past 2 years.
- History of interstitial lung disease.
- Patients with myelodysplastic syndrome/acute myeloid leukemia
- Previous allogenic bone marrow transplant.
- Immuno-compromised patients, e.g., patients who are known to be serologically positive for human immunodeficiency virus (HIV), patients with known active hepatitis (i.e., hepatitis B or C).
- Patients with significant hemorrhage (>30 mL bleeding/episode in previous 3 months) or hemoptysis (>5 mL fresh blood in previous 4 weeks).
- Patients who have had recent (within 2 weeks of registration, or until any wound has completely healed) major thoracic or abdominal surgery prior to study start, or a surgical incision that is not fully healed.
- History of stroke or transient ischemic attack within six months.
- Patients that are receiving other anti-cancer therapy (except patient currently progressing on treatment with PARP inhibitor), radiotherapy, biological therapy or other novel agent prior to start of study treatment.
- Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the investigator would make the participant inappropriate for entry into the study.
- History of other primary second malignancies (except for adequately treated cutaneous basal or squamous cell carcinoma or carcinoma in situ) within < 3 years.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Initial/Cohort C
Niraparib by mouth (orally), once a day, every day.
Bevacizumab, by vein (intravenously), once every 3 weeks for up to 1 year, then every 6 weeks.
|
Niraparib works by blocking poly(ADP-ribose) polymerases (PARP) 1 and PARP 2 from working.
PARP 1 and PARP 2 are proteins that are involved in cell growth, cell survival, and cell death, including cancer cells.
It is believed that blocking PARP1 and PARP 2 from working will slow or stop the growth of cancer cells.
Other Names:
Bevacizumab is a chemotherapy drug commonly used for the treatment of various cancers.
|
Experimental: Cohort A
Niraparib by mouth (orally), once a day, every day. Bevacizumab, by vein (intravenously), once every 3 weeks for up to 1 year, then every 6 weeks. Dostarlimab, by vein (intravenously), once every 3 weeks for 4 doses, then every 6 weeks afterwards. |
Niraparib works by blocking poly(ADP-ribose) polymerases (PARP) 1 and PARP 2 from working.
PARP 1 and PARP 2 are proteins that are involved in cell growth, cell survival, and cell death, including cancer cells.
It is believed that blocking PARP1 and PARP 2 from working will slow or stop the growth of cancer cells.
Other Names:
Bevacizumab is a chemotherapy drug commonly used for the treatment of various cancers.
Dostarlimab is a monoclonal antibody.
Antibodies are proteins that are naturally found in the blood stream that fight infections.
A monoclonal antibody is a special kind of antibody that is created in a laboratory that seeks out specific proteins in the body that may be involved in cancers to stop tumor growth.
Dostarlimab attaches to PD-1 and inhibits the interaction of PD-L1 and PD-L2 with PD-1.
|
Experimental: Cohort B
Paclitaxel, by vein (intravenously), once a week. Bevacizumab, by vein (intravenously), once every 3 weeks for up to 1 year, then every 6 weeks. Dostarlimab, by vein (intravenously), once every 3 weeks for 4 doses, then every 6 weeks afterwards. |
Bevacizumab is a chemotherapy drug commonly used for the treatment of various cancers.
Dostarlimab is a monoclonal antibody.
Antibodies are proteins that are naturally found in the blood stream that fight infections.
A monoclonal antibody is a special kind of antibody that is created in a laboratory that seeks out specific proteins in the body that may be involved in cancers to stop tumor growth.
Dostarlimab attaches to PD-1 and inhibits the interaction of PD-L1 and PD-L2 with PD-1.
Paclitaxel is a chemotherapy drug commonly used for the treatment of various cancers.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percentage of participants that achieve biomarker-guided treatment
Time Frame: 3 years
|
3 years
|
Response rate percentage
Time Frame: 3 years
|
3 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Overall response rate for Cohort A
Time Frame: 3 years
|
3 years
|
Overall response rate for Cohort B
Time Frame: 3 years
|
3 years
|
Overall response rate for initial cohort/Cohort C
Time Frame: 3 years
|
3 years
|
Progression-free survival rate for initial cohort/Cohort C
Time Frame: 3 years
|
3 years
|
Progression-free survival rate for initial cohort/Cohort A
Time Frame: 3 years
|
3 years
|
Progression-free survival rate for initial cohort/Cohort B
Time Frame: 3 years
|
3 years
|
CA125 response rate for initial cohort/Cohort C
Time Frame: 3 years
|
3 years
|
CA125 response rate for Cohort A
Time Frame: 3 years
|
3 years
|
CA125 response rate for Cohort B
Time Frame: 3 years
|
3 years
|
Disease control rate for initial cohort/Cohort C
Time Frame: 3 years
|
3 years
|
Disease control rate for Cohort A
Time Frame: 3 years
|
3 years
|
Disease control rate for Cohort B
Time Frame: 3 years
|
3 years
|
Percentage of participants with adverse events in the initial cohort/Cohort C
Time Frame: 3 years
|
3 years
|
Percentage of participants with adverse events in Cohort A
Time Frame: 3 years
|
3 years
|
Percentage of participants with adverse events in Cohort B
Time Frame: 3 years
|
3 years
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Stephanie Lheureux, M.D., Princess Margaret Cancer Centre
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Genital Neoplasms, Female
- Endocrine System Diseases
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Endocrine Gland Neoplasms
- Fallopian Tube Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Genital Diseases
- Genital Diseases, Female
- Ovarian Neoplasms
- Fallopian Tube Neoplasms
- Carcinoma, Ovarian Epithelial
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Antineoplastic Agents, Immunological
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Poly(ADP-ribose) Polymerase Inhibitors
- Paclitaxel
- Bevacizumab
- Niraparib
- Dostarlimab
Other Study ID Numbers
- Re-VOLVE
- 21-5915 (Other Identifier: University Health Network)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ovarian Cancer
-
Roswell Park Cancer InstituteCompletedFallopian Tube Carcinoma | Primary Peritoneal Carcinoma | Stage IIA Ovarian Cancer | Stage IIB Ovarian Cancer | Stage IIC Ovarian Cancer | Stage IIIA Ovarian Cancer | Stage IIIB Ovarian Cancer | Stage IIIC Ovarian Cancer | Stage IV Ovarian Cancer | Stage IA Ovarian Cancer | Stage IB Ovarian Cancer | Stage IC... and other conditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedCancer Survivor | Stage IIIA Ovarian Epithelial Cancer | Stage IIIB Ovarian Epithelial Cancer | Stage IIIC Ovarian Epithelial Cancer | Stage IIA Ovarian Epithelial Cancer | Stage IIB Ovarian Epithelial Cancer | Stage IIC Ovarian Epithelial Cancer | Stage IA Ovarian Epithelial Cancer | Stage IB Ovarian... and other conditionsUnited States
-
Massachusetts General HospitalJohns Hopkins University; M.D. Anderson Cancer Center; National Cancer Institute... and other collaboratorsRecruitingOvarian Neoplasms | Fallopian Tube Neoplasms | Stage III Ovarian Cancer AJCC v8 | Stage IIIA Ovarian Cancer AJCC v8 | Stage IIIA1 Ovarian Cancer AJCC v8 | Stage IIIA2 Ovarian Cancer AJCC v8 | Stage IIIB Ovarian Cancer AJCC v8 | Stage IIIC Ovarian Cancer AJCC v8 | Stage IV Ovarian Cancer AJCC v8 | Stage... and other conditionsUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedOvarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Serous Cystadenocarcinoma | Stage IV Ovarian Germ Cell Tumor | Ovarian Sarcoma | Malignant Ovarian Epithelial Tumor | Ovarian Carcinosarcoma | Ovarian Brenner Tumor | Ovarian Mucinous... and other conditionsUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedStage IIA Fallopian Tube Cancer | Stage IIA Ovarian Cancer | Stage IIB Fallopian Tube Cancer | Stage IIB Ovarian Cancer | Stage IIC Fallopian Tube Cancer | Stage IIC Ovarian Cancer | Stage IIIA Fallopian Tube Cancer | Stage IIIA Ovarian Cancer | Stage IIIA Primary Peritoneal Cancer | Stage IIIB Fallopian... and other conditionsUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedCaregiver | Stage IIIA Ovarian Cancer | Stage IIIB Ovarian Cancer | Stage IIIC Ovarian Cancer | Stage IV Ovarian CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Eve RodlerNot yet recruitingBreast Cancer | Ovarian Cancer | Breast Neoplasm | Breast Carcinoma | Breast Cancer Stage IV | Breast Cancer Stage I | Breast Cancer Stage II | Invasive Breast Cancer | Cancer, Breast | Breast Cancer Stage III | Ovary Cancer | Malignant Tumor of Breast | Ovarian Cancer Stage IIIC | Ovarian Cancer Stage IV | Ovarian Cancer... and other conditionsUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)RecruitingStage IIIA Ovarian Cancer | Stage IIIB Ovarian Cancer | Stage IIIC Ovarian Cancer | Stage IV Ovarian CancerUnited States
-
University of WashingtonMinnesota Ovarian Cancer AllianceTerminatedStage III Ovarian Cancer AJCC v8 | Stage IIIA Ovarian Cancer AJCC v8 | Stage IIIA1 Ovarian Cancer AJCC v8 | Stage IIIA2 Ovarian Cancer AJCC v8 | Stage IIIB Ovarian Cancer AJCC v8 | Stage IIIC Ovarian Cancer AJCC v8 | Stage IV Ovarian Cancer AJCC v8 | Stage IVA Ovarian Cancer AJCC v8 | Stage IVB Ovarian... and other conditionsUnited States
Clinical Trials on Niraparib
-
Tesaro, Inc.Completed
-
Virginia Commonwealth UniversityGlaxoSmithKline; Puma Biotechnology, Inc.RecruitingOvarian Cancer | Advanced Solid TumorUnited States
-
Fudan UniversityRecruitingTreatment EfficacyChina
-
Tesaro, Inc.Completed
-
Chongqing University Cancer HospitalRecruiting
-
Hunan Cancer HospitalUnknown
-
Abramson Cancer Center at Penn MedicineActive, not recruitingProstate AdenocarcinomaUnited States
-
German Breast GroupGlaxoSmithKline; Stemline Therapeutics, Inc.Not yet recruitingBRCA1 Mutation | BRCA2 Mutation | PALB2 Gene Mutation | Hormone Receptor Positive HER-2 Negative Breast Cancer | Advanced or Metastatic Breast CancerGermany
-
Sun Yat-sen UniversityRecruitingNasopharyngeal CarcinomaChina
-
MedSIRNot yet recruitingOvarian Cancer | Oligometastatic Disease | Serous Ovarian Tumor